Organization
Bristol-Myers Squibb Company
Topic
All Topics
People
Find news about people
Alumni
Find news on alumni of any org
Industries
Find news on a particular market
Your Contacts
Find news on your contacts
Sign up for free daily alerts on this feed:
By pressing Sign Up, you agree to our Terms of Use, Privacy Policy, and the LexisNexis Terms & Conditions

Follow

Change Feed
Bristol-Myers Squibb Company
... including 15 years as a leader in preclinical and clinical development at Bristol-Myers Squibb, Five Prime Therapeutics, Clovis Oncology and Genentech. Currently Senior Vice President, ...
... million related to the amendment of the Company's license agreement with Bristol-Myers Squibb Company (BMS) during the first quarter of 2018, increases in direct costs ...
... the marketSome of the key players operating in this market are Bayer, Bristol-Myers Squibb, Eisai, and Exelixis. Collaborations for development, broader product portfolios, and regional ...
... such as Abbott, Abbvie, Actavis, Amgen, Astellas, AstraZeneca, Baxter, Bayer, Biogen Idec, BMS, Celgene, Eisai, Eli Lilly, Gilead, GSK, J&J, Kyowa Hakko, Merck, Mitsubishi, Mylan, ...
... the market. For instance, in March 2017, Foundation Medicine collaborated with Bristol-Myers Squibb Company, as a result of which Bristol-Myers Squibb could deploy Foundation Medicine's ...
... key players of the market including Roche holding AF, Novartis International AG, Bristol-Myers Squibb and Celgene Corporation. Key Topics Covered: 1. Overview 2. Global Orphan ...
... one or more of the therapeutic development and commercialization programs of Bristol-Myers Squibb Company ("BMS"). Initial-phase development activities under SOW Two are complete and the ...
... 30, 2018. "We are pleased with the progress across our pipeline, including BMS's ongoing randomized Phase 2 clinical trial to evaluate cabiralizumab and OPDIVO® with ...
... Amgen collaboration, an increase of $1.4 million in revenue related to the BMS collaboration, and an increase of $0.7 million in revenue from the collaboration ...
... to an increase in revenue related to the collaboration agreement with Bristol-Myers Squibb Company. R&D Expenses: Research and development (R&D) expenses were $21.4 million in ...
Subscribe now for full coverage on Bristol-Myers Squibb Company
Start My Free Trial